This procedural ruling does not change the fundamental case risk for GSK. The antitrust litigation continues in discovery; monitor for any future summary judgment motions or settlement discussions. The ruling may delay case progression but has no immediate financial impact.
GSK drugs
GSK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 1 $54.99entry
- T+1 · 8mo ago +1.25%α +1.16% · $55.67
- T+5 · 7mo ago +4.23%α +0.47% · $57.31
- T+20 · 7mo ago −6.57%α −16.25% · $51.37
- T+60 · 5mo ago −4.82%α −18.20% · $52.34
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
In the long-running Lamictal reverse-payment antitrust case, the District Court for the District of New Jersey vacated a magistrate's order that had permitted five new expert reports from GSK and Teva without reviewing their content. The court found the magistrate's decision clearly erroneous and remanded for further proceedings, requiring the magistrate to assess whether the reports were within the scope of the scheduling order. This procedural setback for GSK increases uncertainty but does not resolve the underlying antitrust claims.
Court Ruling Details
Key Facts
- District court vacated magistrate's order allowing new expert reports without content review
- Case involves allegations of illegal reverse-payment settlement to delay generic Lamictal
- Matter remanded to magistrate for further proceedings to determine if reports comply with scheduling order
Financial Impact
No monetary damages awarded; procedural ruling on expert discovery
Risk Factors
- Potential adverse antitrust ruling if case proceeds to trial or settlement
- Discovery may expand scope of liability or damages
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-1lfpt4w0-GSK |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers